AIM ImmunoTech Advances Pancreatic Cancer Trial with Final Dose in Phase 2 Study
Event summary
- Final subject dosed in Phase 2 DURIPANC trial evaluating Ampligen® + Imfinzi® for metastatic pancreatic cancer.
- Primary endpoint analysis (Clinical Benefit Rate) expected December 2026; topline results due Q1 2027.
- Secondary endpoints (Overall Survival, PFS, biomarker analysis) to be assessed starting June 2027.
- Prior Named Patient Program data showed significant survival improvements in biomarker-stratified subsets.
- Study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center.
The big picture
This milestone marks progress in developing combination immunotherapy for pancreatic cancer, a notoriously difficult-to-treat indication. The study's focus on biomarker stratification reflects growing industry emphasis on personalized oncology approaches. Positive results could position Ampligen as a key component in next-generation pancreatic cancer regimens, though competition in immuno-oncology remains intense.
What we're watching
- Biomarker Validation
- Whether exploratory biomarker data can identify 'super-responder' subsets to support Phase 3 design.
- Survival Outcomes
- The magnitude of OS and PFS improvements in the Phase 2 results compared to historical controls.
- Regulatory Pathway
- The pace at which AIM can transition from exploratory Phase 2 to pivotal Phase 3 trials.
Related topics